This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow
by Zacks Equity Research
On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.
5 Healthcare Stocks Poised to Beat Earnings Estimates in Q1
by Zacks Equity Research
Earnings results of healthcare sector are likely to reflect solid demand for its products and services from aging population and the growing incidence of COVID-19 illness.
Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.
Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results
by Nalak Das
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) successfully attains EUA from the FDA as well as receives the CE Mark in Europe for its COVID-19 diagnostic test.
Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical (ISRG) first-quarter results benefit from strong growth across all businesses and higher revenues.
Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts
by Zacks Equity Research
To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.
Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance
by Zacks Equity Research
Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.
New Strong Buy Stocks For April 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) Q1 earnings are likely to reflect better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth.
Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) recently-launched COVID-19 test service anticipated to have contributed to Q1 revenues.
Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?
by Zacks Equity Research
Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.
Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.
U.S. Economy Likely to Reopen in May: 5 Top Growth Picks
by Nalak Das
Although the death toll continues to go up in the United States, the curves related to hospitalization, intensive-care check-ins and intubations are gradually flattening.
Why the Earnings Surprise Streak Could Continue for Chemed (CHE)
by Zacks Equity Research
Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Chemed (CHE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Chemed (CHE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Chemed (CHE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
New Strong Buy Stocks for April 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: